{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:48:26Z","timestamp":1772351306165,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1093\/eurheartj\/ehi216","type":"journal-article","created":{"date-parts":[[2005,3,22]],"date-time":"2005-03-22T01:13:03Z","timestamp":1111453983000},"page":"951-952","source":"Crossref","is-referenced-by-count":3,"title":["Should brain natriuretic peptides be measured in patients with aortic valve disease?"],"prefix":"10.1093","volume":"26","author":[{"given":"Omid","family":"Salehian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"key\n\t\t\t\t20171012004631_EHI216C1","doi-asserted-by":"crossref","unstructured":"Bonow RO, Carbello B, deLeon AC et al. ACC\/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology\/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol1998;32:1486\u20131588.","DOI":"10.1016\/S0735-1097(98)00454-9"},{"key":"key\n\t\t\t\t20171012004631_EHI216C2","doi-asserted-by":"crossref","unstructured":"Lung B, Gohlke-Barwolf C, Tornos P et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J2002;23:1252\u20131266.","DOI":"10.1053\/euhj.2002.3320"},{"key":"key\n\t\t\t\t20171012004631_EHI216C3","doi-asserted-by":"crossref","unstructured":"Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation2003;107:1884\u20131890.","DOI":"10.1161\/01.CIR.0000060533.79248.0C"},{"key":"key\n\t\t\t\t20171012004631_EHI216C4","doi-asserted-by":"crossref","unstructured":"Lim P, Monin JL, Monchi M et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J2004;25:2048\u20132053.","DOI":"10.1016\/j.ehj.2004.09.033"},{"key":"key\n\t\t\t\t20171012004631_EHI216C5","doi-asserted-by":"crossref","unstructured":"Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation2004;109:2302\u20132308.","DOI":"10.1161\/01.CIR.0000126825.50903.18"},{"key":"key\n\t\t\t\t20171012004631_EHI216C6","doi-asserted-by":"crossref","unstructured":"Weber M, Arnold R, Rau M et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol2004;94:740\u2013745.","DOI":"10.1016\/j.amjcard.2004.05.055"},{"key":"key\n\t\t\t\t20171012004631_EHI216C7","doi-asserted-by":"crossref","unstructured":"Weber M, Arnold R, Rau M et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J2005;26:1023\u20131030. First published on March 21, 2005, doi: 10.1093\/eurheartj\/ehi236.","DOI":"10.1093\/eurheartj\/ehi236"},{"key":"key\n\t\t\t\t20171012004631_EHI216C8","doi-asserted-by":"crossref","unstructured":"Gerber IL, Stewart RA, French JK et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol2003;92:755\u2013758.","DOI":"10.1016\/S0002-9149(03)00849-X"},{"key":"key\n\t\t\t\t20171012004631_EHI216C9","doi-asserted-by":"crossref","unstructured":"Eimer MJ, Ekery DL, Rigolin VH et al. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol2004;94:676\u2013678.","DOI":"10.1016\/j.amjcard.2004.05.043"},{"key":"key\n\t\t\t\t20171012004631_EHI216C10","doi-asserted-by":"crossref","unstructured":"Lainchbury JG, Campbell E, Frampton CM et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol2003;42:728\u2013735.","DOI":"10.1016\/S0735-1097(03)00787-3"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/26\/10\/951\/9623211\/ehi216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T11:55:39Z","timestamp":1586174139000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartj\/article\/26\/10\/951\/515025\/Should-brain-natriuretic-peptides-be-measured-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,21]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,3,21]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehi216","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,5]]},"published":{"date-parts":[[2005,3,21]]}}}